Market Access The benefits of ePI for patients and the planet With one change made by one pharmaceutical company, we could save half a million trees every year. Imagine the impact if the change was made across industry.
Market Access Exploring the potential of FHIRs and e-labelling Fast Healthcare Interoperability Resources (FHIRs) allow fast to bu
News NIH abandons trial of SIGA's mpox drug Another clinical trial has found that SIGA Technologies' antiviral drug TPOXX (tecovirimat) is ineffective as a treatment for mpox.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.